Post-transplant morbidity and mortality in patients with pulmonary fibrosis and telomeric shortening
Marta García Moyano(Hospital de Cruces), María Molina‐Molina(Instituto de Salud Carlos III), Laura Pintado‐Berninches(Centre for Biomedical Network Research on Rare Diseases), Jordi Dorca(Bellvitge University Hospital), Cristina Berastegui(Centro de Investigación Biomédica en Red de Enfermedades Respiratorias), Rosario Perona(Instituto de Salud Carlos III), Lurdes Planas‐Cerezales(Bellvitge University Hospital), Miriam Bullich(Corporació Sanitària Parc Taulí), Vanesa Vicens(Bellvitge University Hospital), Elena Hernández García, Ana Montes(Guy's and St Thomas' NHS Foundation Trust), Belén López-Muñíz(Hospital Universitario Infanta Leonor), Antonio Román(Vall d'Hebron Hospital Universitari)
Cited by 1
Related Papers
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
|The Lancet Oncology|2021|614
Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2019|343
Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
|BMC Pulmonary Medicine|2018|106
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor
|Gynecologic Oncology|2019|104
Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes
|British Journal of Cancer|2022|89